Here is professional, lab-ready content for:
HIV I & II Antigen & Antibody – Rapid, Serum (H0014a)
Test Overview
The HIV I & II Antigen & Antibody Rapid Test is a qualitative screening assay used for the early detection of Human Immunodeficiency Virus (HIV-1 and HIV-2) infection. This test detects both:
Rapid tests are designed to deliver results quickly (typically within 15–30 minutes) and are widely used for initial screening in clinical and point-of-care settings. (Clinicalinfo)
Principle of the Test
This is a rapid immunochromatographic assay that works on antigen-antibody reaction:
-
Detects p24 antigen, which appears early after infection
-
Detects antibodies, produced by the immune system in response to HIV
Combination (4th generation–like) tests help identify infection earlier than antibody-only tests. (HIV Risk Reduction Tool)
Sample Type
Test Method
Turnaround Time (TAT)
Clinical Significance
Result Interpretation
| Result |
Interpretation |
| Non-Reactive |
No detectable HIV antigen/antibody (may require repeat if recent exposure) |
| Reactive |
Suggestive of HIV infection – requires confirmatory testing
|
| Invalid |
Repeat test with fresh sample |
👉 A reactive rapid test is preliminary and must always be confirmed by advanced laboratory methods. (Mayo Clinic Laboratories)
Window Period
Combination tests reduce the diagnostic window compared to antibody-only tests. (Mayo Clinic Laboratories)
Advantages
-
Rapid results
-
Early detection (antigen + antibody)
-
Minimal equipment required
-
Suitable for emergency and point-of-care testing
Limitations
-
Screening test only (not confirmatory)
-
False negatives possible in very early infection
-
False positives may occur → confirmation required
Preparation
Use Case (Lab / Product Listing Tagline)
“Fast, reliable screening for early HIV detection with antigen & antibody combo testing.”
